4CPS-271 Evaluation of the efficacy of anti-PD-L1 immunotherapy in non-microcritical lung cancer in clinical practice

Abstract

Conclusion and relevance Considering the positive results obtained so far, the study of HIPEC with CRS in peritoneal carcinoma continues, to evaluate its effectiveness. The role of the pharmacist was important in participating in the multidisciplinary team in terms of eligibility of patients for treatment, to prepare oncological therapies and in processing the evaluation data.